Pharma Focus Asia

Novigenix and RadioMedix to Develop Neuroendocrine Cancer Precision Diagnostic Test

Tuesday, October 15, 2019

Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced a collaboration agreement with RadioMedix Inc., a radiopharmaceutical company, to develop a precision diagnostic test based on Novigenix’s technology. The test will measure the response in patients with neuroendocrine tumors (NET) treated with Alpha and Beta Peptide Receptor Radionuclide Therapy (PRRT).

In order to effectively monitor the response following PRRT, Novigenix will develop an immune-transcriptomic based precision diagnostic test using its proprietary LITOseek platform to monitor the effectiveness of the treatment in NET patients.

“We are very pleased to collaborate with Novigenix on the development of a molecular signature for the response to therapy, and to detect progressive disease, earlier than any conventional modalities currently available to our NET patients,” said Dr. Ebrahim S. Delpassand, CEO of RadioMedix “Precise measurement of the therapy response against NET is extremely important for the management of NET patients.”

Neuroendocrine tumors (NET) begin in the cells that have traits of both hormone-producing endocrine cells and nerve cells of the body’s neuroendocrine system. They are found throughout the body’s organs and help control many of the body’s functions. All NETs are considered malignant tumors and most of them take years to develop, grow slow but can begin in any part of the body. On average 6.6 individuals per 100,000 people are diagnosed with NET per year. In the US, approximately 12,000 individuals per year are diagnosed with NET and 170,000 are living with the disease. The diagnosis is mainly based on imaging technologies and endoscopy.

“Our goal is to have a precise molecular and highly sensitive and specific diagnostic test to manage patients with NET across the entire course of treatment and follow up,” stated Dr. Jan Groen CEO of Novigenix. “This collaboration with RadioMedix highlights the potential of our immune-transcriptomic approach to potential pharma partners seeking liquid biopsy based precision diagnostic tests.”

Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024